Multiple sclerosis: monotherapy rules.
作者信息
Hauser Stephen L, Josephson S Andrew, Johnston S Claiborne
出版信息
Ann Neurol. 2013 Mar;73(3):A5-6. doi: 10.1002/ana.23886.
PMID:23596013
Abstract
摘要
相似文献
1
Multiple sclerosis: monotherapy rules.多发性硬化症：单一疗法规则
Ann Neurol. 2013 Mar;73(3):A5-6. doi: 10.1002/ana.23886.
2
Editorial: the pitfalls of combination therapy.社论：联合治疗的陷阱
Int MS J. 2006 Nov;13(3):75-6.
3
Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.加拿大多发性硬化症临床诊所网络关于：多发性硬化症中疾病修正药物使用的共识声明。
Can J Neurol Sci. 1999 Nov;26(4):274-5. doi: 10.1017/s0317167100000378.
4
[Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].[治疗技术的后勤保障与描述（使用疾病修正药物——DMD的方案）]
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):93-8.
5
The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.英国多发性硬化症中干扰素-β和醋酸格拉替雷的风险分担计划。6年分析结果。
Pract Neurol. 2016 Feb;16(1):4-6. doi: 10.1136/practneurol-2015-001209. Epub 2015 Oct 1.
6
Interferon beta and glatiramer acetate therapy.干扰素β和醋酸格拉替雷治疗。
Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4.
7
[The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].[使用长期免疫调节药物（疾病修正药物——DMD）——β-干扰素和醋酸格拉替雷治疗多发性硬化症的技术]
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):86-92.
8
The use of interferon Beta and glatiramer acetate in multiple sclerosis.多发性硬化症中干扰素β和醋酸格拉替雷的应用。
Semin Neurol. 2013 Feb;33(1):13-25. doi: 10.1055/s-0033-1343792. Epub 2013 May 25.
9
Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.关于舒海巴尔等人的评论：免疫调节剂疗法对多发性硬化症骨密度的有利影响。
Ir J Med Sci. 2009 Jun;178(2):235-6; author reply 237-8. doi: 10.1007/s11845-009-0275-y. Epub 2009 Jan 31.
10
[Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].β-干扰素和考帕松++在多发性硬化症治疗中的应用问题与前景
Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(4):33-6.
引用本文的文献
1
Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.间充质干细胞和诱导多能干细胞作为治疗多发性硬化症的方法。
Int J Mol Sci. 2015 Apr 24;16(5):9283-302. doi: 10.3390/ijms16059283.
Zotero 插件